What’s the Hardest Part of Getting a Medical Device from Prototype to First Clinical Use? Question: For engineers, FDA consultants, IRB leaders, clinical trial coordinators, MedTech CEOs, and physician-inventors: What is the most underestimated obstacle between a working prototype and its first use in a patient? Eligibility: Experience must include actual product development cycles, not theoretical opinions. Opportunity: Top answers may be invited for a bylined article and highlighted on LinkedIn.

The journey from medical device prototype to first clinical use is shaped by complexities that most innovators overlook. The greatest challenge is not just refining technical features, but harmonizing every aspect of development with real clinical practice and rigorous regulatory demands. Success in the engineering phase can create a false sense of security, because laboratory results rarely predict how a device will perform in the clinic. Devices that excel in bench tests often encounter serious setbacks when exposed to the practical, biological, and ergonomic demands of patient care. Subtle differences in how clinicians interact with a device can expose hidden weaknesses, often resulting in costly design updates once formal clinical evaluation begins. Navigating global regulatory frameworks introduces its own set of demanding hurdles. Regulatory bodies require extensive evidence of safety, performance, and clinical benefit. Every detail must be documented and risks thoroughly assessed. It is not enough to be technically successful you must also build compliance into every stage of development. Relying on preliminary lab results or anecdotes leads to disappointment. Ensuring that every manufactured unit matches the validated prototype is another essential challenge. Design for manufacturability and quality control are foundational elements, not afterthoughts. Failure to harmonize design with manufacturing and quality requirements can prolong timelines, raise costs, and undermine trust among clinicians and regulatory partners. Leaders who succeed in bringing breakthrough devices to patients embrace multidisciplinary collaboration, engage early with regulatory and clinical stakeholders, and focus relentlessly on the realities faced by end-users. The ability to embed frameworks for feedback, risk management, and evidence-based development from the start is what separates ambition from true impact.